Unichem Laboratories Submits FY2025-26 Business Responsibility and Sustainability Report

What Happened ?

Key Details

Key Business Responsibility & Sustainability Highlights:

• Business operations continue to be entirely focused on manufacturing and sale of pharmaceutical products.
• Products are marketed across 65 international markets and 14 Indian states.
• Export sales contributed approximately 97.6% of FY2026 turnover.
• Operations include six manufacturing plants and one R&D centre in India.
• Sustainability governance remains under Board oversight.
• Multiple ESG policies cover all nine National Guidelines on Responsible Business Conduct (NGRBC) principles.
• Three manufacturing locations maintain ISO 14001 and ISO 45001 certifications.
• The company continues investments in renewable energy, water conservation, waste recycling and emissions reduction initiatives.
• Long-term sustainability goals include:
  • Recycling and reuse of 80% treated effluent by FY2027.
  • Recycling or co-processing 60% of waste by FY2028.
  • Reducing Scope 1 & Scope 2 emissions by 10% by FY2030.
  • Continuous reduction in workplace accident frequency.
• During FY2026:
  • 84% of treated effluent was recycled and reused.
  • 53% of waste was managed through recycling, reuse or co-processing.
  • Scope 1 & Scope 2 emissions reduced by 26% versus the baseline year.
  • Accident Frequency Rate and Incident Frequency Rate improved by 18.1%.  

Note:

• The filing primarily updates investors on ESG performance, sustainability governance, environmental management, and responsible business practices rather than announcing commercial developments.  

Risk Analysis

Summary:

• The company identifies regulatory compliance, product quality, environmental management, workplace safety, R&D execution, and supply chain resilience as its principal sustainability-related business risks.

Key Risks:

• Regulatory non-compliance may lead to warning letters, import alerts, penalties or plant shutdowns.
• Product quality failures could affect customer trust and demand.
• Delays in R&D and product launches may impact profitability.
• Supply chain disruptions could increase raw material costs and affect product availability.
• Environmental and workplace safety non-compliance may result in operational interruptions and regulatory action.
• Dependence on energy and water-intensive manufacturing requires continued sustainability investments.  

Worst Case:

• Material regulatory action or operational disruptions resulting from quality, environmental, safety, or compliance failures could adversely affect manufacturing continuity, profitability, and corporate reputation.

Risk Level: Medium

Company Commentary

• Sustainability remains integral to delivering quality pharmaceutical products responsibly.
• The company continues improving resource efficiency across manufacturing operations.
• Internal teams and external partners collaborate to advance sustainability initiatives.
• Investments in technology and automation are intended to strengthen operational excellence while supporting long-term sustainable growth.
• Product quality, regulatory compliance and patient safety remain core business priorities.